BioCentury
ARTICLE | Distillery Therapeutics

Cancer

June 28, 2018 5:52 PM UTC

Mouse studies suggest transferrin-conjugated liposomal nanoparticles loaded with temozolomide and an inhibitor of BET bromodomain proteins could help treat glioma. The liposomal nanoparticles contain distearoylglycerophosphoethanolamine (DSPE) conjugated to polyethylene glycol (PEG) and transferrin, which binds transferrin receptor (TFRC; TFR; CD71) expressed on the brain capillary endothelium, and are loaded with temozolomide and a BET bromodomain inhibitor. In two orthotopic mouse models of glioma, the nanoparticles decreased tumor growth and increased survival and apoptosis and DNA damage in tumor cells compared with free temozolomide plus the bromodomain inhibitor. Next steps could include testing the nanoparticles in additional glioma models...